Skip to main content
BGLC logo

BioNexus Gene Lab Corp.

BGLCNASDAQMaterialsSpecialty Chemicals

$1.06Today:- (-)1Y −77.07%

As of Oct 28, 2026 close

Market cap
$2.57M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.07$5.89
Volume (live)
-
Avg. volume (3M)
7.22K

BioNexus Gene Lab (BGLC) Financial Ratios

For fiscal 2026 (fiscal year ended Dec 31, 2025), BioNexus Gene Lab had return on equity of -35.2%, debt-to-equity of 0.01, a current ratio of 10.46 and return on assets of -30.1%. A current ratio of 10.46 means current assets exceed current liabilities.

BioNexus Gene Lab Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income StatementBalance SheetCash FlowRatios
Scroll to see more
BreakdownFY 2026FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio-2.46---485.24215.96
P/S Ratio1.290.530.9615.1027.2920.74
P/B Ratio1.110.600.9724.7650.8035.47
Price/Tangible Book0.850.600.9724.7650.8035.47
Price/FCF-5.09--331.6260792.561802.86
Price/OCF-5.19--299.0739809.47427.52
Enterprise Value Ratios
EV/Revenue0.760.120.3414.9727.1720.69
EV/EBITDA-2.01---316.52358.35
EV/EBIT-1.90---343.88415.74
EV/FCF-3.00--328.7460523.491798.18
Profitability & Returns
Return on Equity (ROE)-35.24%-17.78%-32.21%-5.14%10.86%28.11%
Return on Assets (ROA)-30.12%-10.86%-18.85%-1.50%6.70%6.25%
Return on Invested Capital (ROIC)-65.32%-47.15%-71.66%-4.53%16.67%22.58%
Return on Capital Employed (ROCE)-34.45%-22.40%-31.10%-3.30%14.60%8.40%
Leverage & Solvency Ratios
Debt/Equity0.010.030.010.010.010.02
Debt/EBITDA-0.06---0.070.19
Debt/FCF-0.09--0.1112.830.94
Liquidity Ratios
Current Ratio10.463.814.933.003.072.37
Quick Ratio8.883.104.242.522.392.02
Efficiency Ratios
Asset Turnover0.750.870.971.191.362.01
Inventory Turnover6.146.517.987.748.2216.34
Yield & Distribution Ratios
Earnings Yield-40.68%-31.80%-28.08%-0.22%0.21%0.46%
FCF Yield-19.64%-46.17%-21.05%0.30%0.00%0.06%
Buyback Yield-4.20%-12.24%-10.17%-0.99%-66.36%-19.16%
Total Return-4.20%-----

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About BioNexus Gene Lab Financial Ratios

What is BioNexus Gene Lab's return on equity?

BioNexus Gene Lab's return on equity (ROE) was -35.2% for fiscal 2026 (period ended Dec 31, 2025).

What is BioNexus Gene Lab's debt-to-equity ratio?

BioNexus Gene Lab's debt-to-equity ratio was 0.01 for fiscal 2026 (period ended Dec 31, 2025).

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition